IMMUTEP Ltd
PRRUFDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
eftilagimod alpha | Phase 2 | HNSCC | - | - |
Frequently asked questions
What is in IMMUTEP Ltd's drug pipeline?→
CatalystAlert tracks 1 drug candidate in IMMUTEP Ltd's (PRRUF) pipeline across Phase 2. Its lead program is eftilagimod alpha (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is IMMUTEP Ltd's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for IMMUTEP Ltd (PRRUF) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track PRRUF biotech catalysts?→
Add PRRUF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow IMMUTEP Ltd's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.